Emyria Ltd (ASX:EMD)'s Michael Winlo tells Proactive's Andrew Scott they've contracted a leading North American drug manufacturer to deliver a range of novel, synthetic cannabinoid-based (CBD) medicines for its Australian and US drug registration program. They've engaged Altasciences, an award-winning contract drug manufacturer with more than 1,000 employees and seven locations across the US and Canada, to deliver a range of proprietary, synthetic cannabinoid-based capsules utilising a unique drug delivery approach.
Emyria to accelerate FDA and TGA CBD registration programs with Altasciences deal
